argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
29 mei 2015 - 07:00
Statutaire naam
argenx SE
Titel
arGEN-X presents preliminary efficacy and expanded safety data from Phase I trial of ARGX-111 at ASCO
Bericht
- Safe dose established for next stage studies
- Biological activity observed in MET-amplified cancer patient
Breda, the Netherlands/Ghent, Belgium, 29 May 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, will present the results of a Phase I, first-in-human dose escalation study of ARGX-111, a monoclonal antibody targeting c-Met in patients with solid tumors, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The company will present an abstract of the data on Saturday, May 30th, from 8:00 a.m. - 11:30 a.m. as part of the poster session on Development Therapeutics.
Gerelateerde downloads
Datum laatste update: 19 december 2025